.
BioEnterprise

Athersys Strikes Licensing Deal with New Japanese Partner

Athersys, a Cleveland biotech company, has sold the exclusive rights to commercialize its stem cell technology to Healios K.K, a Japanese company. Athersys will receive an up-front payment of $15 million, is eligible to receive regulatory and development milestone payments of up to $30 million and sales milestones of up to approximately $185 million.

Read More  >